# Cartus Chan

> Cartus Chan is a private equity investor at HarbourVest Partners backing Pharmaceutical. See 3 investments, check sizes, portfolio and contact details…

- Type: Angel Investor
- Fund: [HarbourVest Partners](https://shizune.co/investors/profile/harbourvest-partners)
- Total investments: 3
- Last investment: Dec 2017
- Lead investor: 0%
- Last updated: Oct 2026
- LinkedIn: https://www.linkedin.com/in/cartus-chan/?originalSubdomain=hk

Cartus Chan is a Principal at HarbourVest Partners. He attended The University of Chicago Booth School of Business.

## Contacts

5 contacts available for Cartus Chan: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/cartus-chan?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Pharmaceutical | 2 | 67% |
| Education | 1 | 33% |
| Health Care | 1 | 33% |
| Outsourcing | 1 | 33% |
| Biotechnology | 1 | 33% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Private Equity | 2 | 67% |
| Funding Round | 1 | 33% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| India | 1 | 33% |
| Australia | 1 | 33% |
| United States | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Ascender HCM | Ascender is the payroll and learning outsourcing provider. | $77.1M | Private Equity | Dec 21, 2017 | https://www.ascenderhcm.com/ |
| Albany Molecular Research | “Albany Molecular Research Inc. provides scientific services, products and technologies that improve quality of life while delivering excellence, value and maximum return.”Albany Molecular Research, Inc. (NASDAQ: AMRI) is a global contract research and manufacturing organization offering customers fully integrated drug discovery, development, andmanufacturing services. |  |  | Jan 01, 2012 | http://amriglobal.com |
| Mankind Pharma | Mankind Pharma aspires to aid the community in a healthy life by formulating, developing, commercializing, and delivering affordable and accessible medicines that satisfy urgent medical needs. Mankind Pharma came into existence in 1986, and in 1991, the company was formed into a legal corporation. However, it actively started working as afully-integrated pharmaceutical company in 1995. Today, Mankind has an employee base of over 14,000 and is racing towards $1 Billion.The company takes great pride in the success of its products ranging from Pharma, OTC, and FMCG brands like Manforce Condoms, Manforce Tablets, Manforce Staylong Gel, Unwanted 72, Prega News, Adiction, Gas-O-Fast, Kaloree 1 and many others. | $24M | Private Equity | Apr 30, 2007 | https://www.mankindpharma.com |

3 of 3 investments shown.

## Co-investors
- [ChrysCapital](https://shizune.co/investors/profile/chrys-capital) — VC Fund, 1 deal together

## About HarbourVest Partners

VC Fund · Boston, United States

HarbourVest is an independent investment firm that provides innovative private equity solutions to institutional clients worldwide. As one of the first private equity fund-of-funds, they have a long and distinguished history of investing in venture, buyout, and mezzanine and distressed markets in the U.S., Europe, Asia Pacific, and emergingmarkets through primary partnerships, secondary purchases, and direct investments.

5 contacts available at HarbourVest Partners.

| Name | Title | Profile |
| --- | --- | --- |
| Cartus Chan | Principal | https://shizune.co/investors/profile/cartus-chan |
| Corentin Du Roy | Managing Director & Direct Investments | https://shizune.co/investors/profile/corentin-du-roy |
| John Nelson | Fund Controller | https://shizune.co/investors/profile/john-nelson-3 |
| Kapil Kirpalani | Vice President, Legal and Compliance Officer | https://shizune.co/investors/profile/kapil-kirpalani |
| Peter Lipson | Managing Director, Boston | https://shizune.co/investors/profile/peter-lipson |

## Similar investors

### Similar stage
- [Business Growth Fund](https://shizune.co/investors/profile/business-growth-fund) — VC Fund
- [Maven Capital Partners](https://shizune.co/investors/profile/maven-capital-partners) — VC Fund
- [Foresight Group](https://shizune.co/investors/profile/foresight-group) — VC Fund

## FAQ

### What does Cartus Chan invest in?

Cartus Chan invests primarily in Pharmaceutical, Education and Health Care startups, most often at Private Equity and Funding Round stage. Most of the 3 investments tracked by Shizune back companies in India. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Cartus Chan?

Public channels for Cartus Chan include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Cartus Chan last invest?

The most recent investment recorded for Cartus Chan closed in Dec 2017. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co